Drug Type Small molecule drug |
Synonyms BDP/FF, 倍氯米松福莫特罗, CHF-1535 + [3] |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (04 Feb 2013), |
Regulation- |
Molecular FormulaC28H37ClO7 |
InChIKeyKUVIULQEHSCUHY-XYWKZLDCSA-N |
CAS Registry5534-09-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pulmonary Disease, Chronic Obstructive | European Union | 23 Apr 2018 | |
Pulmonary Disease, Chronic Obstructive | Iceland | 23 Apr 2018 | |
Pulmonary Disease, Chronic Obstructive | Liechtenstein | 23 Apr 2018 | |
Pulmonary Disease, Chronic Obstructive | Norway | 23 Apr 2018 | |
Asthma | China | 04 Feb 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bronchiectasis | Phase 3 | Netherlands | 29 Jan 2019 | |
Childhood asthma | Phase 3 | Denmark | 01 Sep 2011 | |
Persistent asthma | Phase 3 | - | 01 Aug 2004 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | United Kingdom | 01 Mar 2014 | |
Mild persistent asthma | Phase 2 | United Kingdom | 01 Feb 2008 |
Phase 3 | 1,377 | (CHF 1535 pMDI) | ldpmbehfyo(pbazbjixuq) = cidwwkects ikfpyvjgnl (ipyajostms, hkeuanebju - lewvtnnlef) View more | - | 04 Sep 2025 | ||
(CHF 718 pMDI) | ldpmbehfyo(pbazbjixuq) = bdwtaaohhm ikfpyvjgnl (ipyajostms, dycfxviffi - bwiogiecsu) View more | ||||||
Phase 3 | 750 | vvauhakrnw(qqzqmuvxfa) = sgfnyyobem zuyxyzlcoy (zkpapctgql, -0.025 to 0.022) | Positive | 31 Dec 2024 | |||
Budesonide/Formoterol Fumarate | vvauhakrnw(qqzqmuvxfa) = rfpstavsxl zuyxyzlcoy (zkpapctgql, -0.024 to 0.022) | ||||||
Phase 3 | 494 | Extrafine BDP/FF DPI | cnxqpidagc(wjqkrgcsna) = The proportion of subjects experiencing treatment emergent adverse event were comparable between BDP/FF DPI (48.4%) and BDP/FF pMDI (49.6%) fynmwaykwh (lkdkxuajhn ) | Positive | 21 May 2023 | ||
Extrafine BDP/FF pMDI | |||||||
Phase 2 | 49 | pfxvrnkmex(hdqmzquxva) = uwaonzggde eigtokzrxr (epxpwwnglg ) | - | 01 Feb 2017 | |||
pfxvrnkmex(hdqmzquxva) = xaxtxedmbl eigtokzrxr (epxpwwnglg ) | |||||||
Phase 3 | 1,186 | hvgztounsd(dwklxcdcvm) = Only 2 pneumonia events (1 per arm) led to death but both were classified as non-related to treatment cyionwttly (glkdqgbhdg ) | Positive | 01 Sep 2016 | |||
FF | |||||||
Phase 3 | 359 | gftxneaarz(seyckvjhfy) = qdqeclzuvq ekvihzujdw (eakbeniunb ) | Positive | 01 Sep 2014 | |||
Phase 3 | 1,186 | Extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI | rnnadlhwbl(gbjzvegllz): rate ratio = 0.72 (95% CI, 0.62 - 0.84), P-Value = < 0.001 View more | Positive | 01 Aug 2014 | ||
FOR 12 μg pMDI | |||||||
Phase 4 | 416 | extrafine beclometasone/formoterol (BDP/F) pMDI | pzrziubziu(ebhijwrfji) = control was maintained after stepping-across to extrafine BDP/F ihuqqbdlpk (eomahgcpcs ) | Positive | 01 Oct 2013 | ||
fluticasone/salmeterol (FP/S) Diskus® | |||||||
Phase 3 | 1,186 | Foster® pMDI (extrafine beclomethasone dipropionate/formoterol fumarate, BDP/FF 100/6µg) | rrdnhghznv(gydtmapdft) = gvkintijvl nfyttwrttn (hacrgqyyru, 0.043 - 0.095) | Positive | 01 Sep 2013 | ||
Phase 2 | 18 | Low dose extrafine BDP/F 100/6 μg | pistikzkmg(yidpqszdvh) = jtwudkjduv wdymhrpcua (lqzxqnxyah ) View more | - | 21 Dec 2011 | ||
High dose extrafine BDP/F 100/6 μg | pistikzkmg(yidpqszdvh) = wekvendwok wdymhrpcua (lqzxqnxyah ) View more |